Abingworth Management Ltd Company Profile

16:39 EDT 25th September 2017 | BioPortfolio

Abingworth is a vital player among life science venture capital investors on both sides of the Atlantic, with offices in London and Palo Alto. Abingworth has funds under management of over $300 million, 8 experienced professionals and backed more than 60 life science firms, most of which have gone public or been acquired. Abingworth is a strongly science-driven organization and has the resources and approach to assist seed stage start-up companies and take them beyond the IPO stage.


38 Jermyn Street
United Kingdom


Phone: 0207 534 1500
Fax: 0207 287 0480

News Articles [571 Associated News Articles listed on BioPortfolio]

Takeda and Abingworth invest $100mm in GammaDelta Therapeutics; Takeda has option to buy

Takeda Pharmaceutical Co. Ltd., through its Millennium Pharmaceuticals/Takeda Oncology unit, and Abingworth agreed to together commit up to $100mm in funding to Abingworth-seeded biotech GammaDelta Th...

Takeda, Abingworth Infuse $100 Million Into a Tiny Biotech, Sealing an Option for M&A

  Life Sciences Jobs   ...

Gamma, delta, exit

Why Abingworth capped its upside in build-to-buy deal for GammaDelta Therapeutics. Plus: Edico B round draws Dell.

Takeda Negotiates Right to Buy GammaDelta for T Cell Immunotherapeutics Platform

Takeda has negotiated an exclusive right to acquire GammaDelta Therapeutics as part of a strategic collaboration to progress  the U.K-start-up’s human tissue-derived gamma delta (γδ) T cell p...

Takeda Negotiates Right to Buy GammaDelta for T-Cell Immunotherapeutics Platform

Takeda has negotiated an exclusive right to acquire GammaDelta Therapeutics as part of a strategic collaboration to progress the U.K. startup’s human tissue-derived gamma delta (γδ) T-cell platfor...

Proteon grosses $22mm through private preferred share sale

Proteon Therapeutics Inc. (treatments for kidney and vascular diseases) grossed $22mm through the private sale of 22k Series A preferred shares at $1k. The stock is convertible into 22.1mm common at $...

VenatoRx secures $42mm in Series B financing

Antibacterials developer VenatoRx Pharmaceuticals Inc. raised $42mm in its Series B financing led by Versant Ventures, which was joined by Abingworth and Foresite Capital. According to the Form D, 42 ...

VenatoRx Pharmaceuticals raises $42m in new funding round

VenatoRx Pharmaceuticals has raised $42m in a Series B funding round led by Versant Ventures and joined by Abingworth and Foresite Capital.

PubMed Articles [2475 Associated PubMed Articles listed on BioPortfolio]

Exploring stroke survivors' and physiotherapists' views of self-management after stroke: a qualitative study in the UK.

Stroke is a sudden-onset condition with long-term consequences. Self-management could help address long-term consequences of stroke. Stroke survivors' and health professionals' views of self-managemen...

Surgical management of lung metastases.

Management of pulmonary metastases has evolved considerably over the last few decades but is still controversial. The surgical management of lung metastases is outlined, discussing the preoperative ma...

Effects of self-management on chronic kidney disease: A meta-analysis.

Self-management programs may facilitate the improvement of outcomes in medical, role, and emotional management and health-related quality of life in patients with chronic kidney disease. Studies on th...

Older Patients' Perspectives on Managing Complexity in CKD Self-Management.

Patients with CKD are asked to perform self-management tasks including dietary changes, adhering to medications, avoiding nephrotoxic drugs, and self-monitoring hypertension and diabetes. Given the ef...

Management of Neurogenic Bladder.

This article provides a comprehensive summary of the clinical approach, investigative modalities and management of a child with neurogenic bladder disease due to myelodysplasia. It is aimed at pediatr...

Clinical Trials [2144 Associated Clinical Trials listed on BioPortfolio]

Hepatitis C Self-Management

The objective of this study is to compare the efficacy of a 6-session hepatitis C self-management workshop to a hepatitis C self-management self-study program. Both interventions are desig...

Contingency Management Treatment Duration

310 alcohol abusing or dependent patients beginning intensive outpatient day treatment at community-based clinics will be randomly assigned to one of four conditions: (a) standard treatmen...

Self-Management Addressing Heart Disease Risk Trial

The purpose of this research study is to learn whether or not people with bipolar disorder can reduce their risk of heart disease and related conditions by having a Care Manager provide se...

Postoperative Canadian Oral Anticoagulation Self-Management (Post-COAGS) Trial

This study will measure the efficacy and safety of an early postoperative anticoagulation self-management program, using the CoaguChek S device, in patients undergoing mechanical valve rep...

A SMART Design for Attendance-based Prize CM

The purpose of this study is to compare different forms of treatment for substance abuse. This study will involve a type of treatment called contingency management, in which patients recei...

Companies [1167 Associated Companies listed on BioPortfolio]

Abingworth Management Ltd

Abingworth is a vital player among life science venture capital investors on both sides of the Atlantic, with offices in London and Palo Alto. Abingworth has funds under management of over $300 millio...

Abingworth Management Inc

Abingworth is a long-established venture capital firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage a...

Avila Therapeutics, Inc.

Avila focuses on design and development of targeted covalent drugs to achieve best-in-class outcomes that cannot be achieved through traditional chemistries. This approach is call...

Intellikine, Inc.

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start ...

RD Management LLC

Specializing in the retail sector for more than 40 years, RD Management owns and operates more than 18 million square feet of neighborhood and community shopping centers throughou...

More Information about "Abingworth Management Ltd" on BioPortfolio

We have published hundreds of Abingworth Management Ltd news stories on BioPortfolio along with dozens of Abingworth Management Ltd Clinical Trials and PubMed Articles about Abingworth Management Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Abingworth Management Ltd Companies in our database. You can also find out about relevant Abingworth Management Ltd Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record